

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI525369

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
Tris Pharma, Inc.	09/26/2024
Park Therapeutics, Inc.	09/26/2024

RECEIVING PARTY DATA

Company Name:	Provident Bank
Street Address:	111 Wood Avenue South
Internal Address:	Suite 200
City:	Iselin
State/Country:	NEW JERSEY
Postal Code:	08830

PROPERTY NUMBERS Total: 18

Property Type	Number
Application Number:	17725673
Application Number:	16955373
Application Number:	11590081
Application Number:	18163818
Application Number:	11918689
Application Number:	18419883
Application Number:	11590228
Application Number:	12076441
Application Number:	11938224
Application Number:	17818733
Application Number:	10912763
Application Number:	10076510
Application Number:	10022353
Application Number:	10323040
Application Number:	11311504
Application Number:	11285113
Application Number:	11998640
Application Number:	11229625

PATENT

CORRESPONDENCE DATA**Fax Number:** 8602189683

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8602756743**Email:** smason@mccarter.com**Correspondent Name:** Sharon Mason**Address Line 1:** McCarter English, LLP**Address Line 2:** 185 Asylum Street**Address Line 4:** Hartford, CONNECTICUT 06103

NAME OF SUBMITTER:	Sharon Mason
SIGNATURE:	Sharon Mason
DATE SIGNED:	09/26/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 13

source=Tris Pharma - Patent Security Agreement(Executed)#page1.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page2.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page3.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page4.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page5.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page6.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page7.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page8.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page9.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page10.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page11.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page12.tiff
source=Tris Pharma - Patent Security Agreement(Executed)#page13.tiff

PATENT SECURITY AGREEMENT

THIS PATENT SECURITY AGREEMENT (this "Patent Security Agreement") dated as of September 26, 2024, by and among Tris Pharma, Inc., a New Jersey corporation ("Tris Pharma") and Park Therapeutics, Inc., a Delaware corporation ("Park Therapeutics", together with Tris Pharma, collectively, the "Grantors", and each, a "Grantor") in favor of Provident Bank, a New Jersey Chartered Savings Bank (the "Lender").

RECITALS

WHEREAS, reference is made to that certain Credit Agreement, dated as of September 26, 2024 (as it may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"; capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement), by and among the Grantors, the other grantors named therein, and the Lender; and

WHEREAS, to secure each Grantor's obligations to the Lender under the Credit Agreement, the Grantors have granted to the Lender a first priority Lien in, among other property, certain intellectual property of each Grantor and as a condition to the effectiveness of the Credit Agreement, each Grantor has agreed to execute and delivery this Patent Security Agreement for recording with all applicable Governmental Authorities, including, but not limited, the United States Patent and Trademark Office.

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, each Grantor and the Lender agree as follows:

Section 1. *Defined Terms.* Capitalized terms used herein without definition are used as defined in the Credit Agreement.

Section 2. *Grant of Security Interest in Patent Collateral.* Each Grantor, as security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, collaterally assigns, pledges, transfers and hypothecates to Lender, and grants to Lender a continuing first priority Lien in all of its right, title and interest in, to and under the following Collateral wherever located, and whether now existing or hereinafter acquired (the "Patent Collateral");

(a) all of its patents and pending patent applications, including, without limitation, those referred to on Schedule 1 hereto, and all inventions described and claimed therein;

(b) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing; and

(c) all rights of any kind whatsoever of such Grantor accruing under any of the foregoing provided by applicable law the United States of America;

(d) any and all claims and causes of action, with respect to any of the foregoing, whether occurring before, on or after the date hereof, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages; and

(e) all income, royalties, proceeds, payments and liabilities at any time due or payable or asserted under and with respect to any of the foregoing.

Section 3. *Recordation.* Each Grantor authorizes the Commissioner for Patents and any other government officials to record and register this Patents Security Agreement upon receipt thereof.

Section 4. *Security Agreement.* The Lien described herein is granted in conjunction with the Lien granted to Lender pursuant to the Security Agreement, dated as of the date hereof, by and among the Grantors, the other grantors thereto and the Lender (the "Security Agreement"). The parties hereby acknowledge and agree that the rights and remedies of the Lender with respect to the Lien in the Patent Collateral described herein, as more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. Nothing contained in this Patent Security Agreement shall be deemed to limit such rights and remedies.

Section 5. *Grantor Remains Liable.* Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, each Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with the Patents owned by it and any applicable Intellectual Property Licenses thereof subject to the Lien hereunder.

Section 6. *Counterparts.* This Patent Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 7. *Governing Law.* THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW JERSEY WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

TRIS PHARMA, INC., a New Jersey corporation, as
Grantor

By: 
Name: Ketan Mehta
Title: Chief Executive Officer


PARK THERAPEUTICS, INC., a Delaware corporation, as
Grantor

By: 
Name: Ketan Mehta
Title: Chief Executive Officer

[Signature Page to Patent Security Agreement]

ACCEPTED AND AGREED
as of the date first above written:

PROVIDENT BANK,
as Lender

By: 

Name:

Title:

Colleen O'Hawley
Vice President

[Signature Page to Patent Security Agreement]

SCHEDULE 3.7
to
Security Agreement

Intellectual Property

PATENTS

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
Formulations containing an ionic mineral-ion exchange resin complex and uses thereof	USA	Tris Pharma, Inc.	10/16/2012	8287848	Active
Formulations containing an ionic mineral-ion exchange resin complex and uses thereof	USA	Tris Pharma, Inc.	08/20/2013	8512688	Active
GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system	USA	Tris Pharma, Inc.	06/06/2023	11666546	Active
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system	USA	Tris Pharma, Inc.	04/18/2023	18302525	Pending
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	04/07/2015	8999386	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	11/10/2015	9180100	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	03/29/2016	9295642	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	12/19/2017	9844544	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	01/17/2017	9545399	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	12/19/2017	9844545	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	12/17/2019	10507203	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	12/08/2020	10857143	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	04/25/2023	11633389	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	08/31/2021	11103494	Active
Methylphenidate extended release chewable tablet	USA	Tris Pharma, Inc.	08/31/2021	11103495	Active
Methylphenidate Extended Release Chewable Tablet	USA	Tris Pharma, Inc.	03/15/2023	18184443	Pending
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	11/22/2011	8062667	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	12/25/2012	8337890	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	06/19/2012	8202537	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	07/23/2013	8491935	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	12/03/2013	8597684	Active
Modified release formulations containing	USA	Tris Pharma, Inc.	07/29/2014	8790700	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
drug-ion exchange resin complexes					
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	06/10/2014	8747902	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	11/11/2014	8883217	Active
Modified release formulations containing drug—ion exchange resin complexes	USA	Tris Pharma, Inc.	12/20/2016	9522191	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	12/01/2015	9198864	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	01/24/2017	9549989	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	06/13/2017	9675704	Active
Modified release formulations containing drug - ion exchange resin complexes	USA	Tris Pharma, Inc.	06/13/2017	9675703	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	01/08/2019	10172958	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	10/02/2018	10086087	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	06/02/2020	10668163	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	03/02/2021	10933143	Active
Modified release formulations containing drug-ion exchange resin complexes	USA	Tris Pharma, Inc.	02/18/2022	17675842	Pending
Benzonatate modified release solid tablets and capsules	USA	Tris Pharma, Inc.	11/10/2015	9180104	Active
Benzonatate modified release solid tablets and capsules	USA	Tris Pharma, Inc.	08/09/2016	9408823	Active
Benzonatate modified release solid tablets and capsules	USA	Tris Pharma, Inc.	01/16/2018	9867797	Active
Benzonatate modified release solid tablets and capsules	USA	Tris Pharma, Inc.	02/08/2022	11241411	Active
Benzonatate modified release solid tablets and capsules	USA	Tris Pharma, Inc.	02/06/2024	11890267	Active
Orally effective methylphenidate extended release powder and aqueous suspension product	USA	Tris Pharma, Inc.	10/16/2012	8287903	Active
Orally effective methylphenidate extended release powder and aqueous suspension product	USA	Tris Pharma, Inc.	06/18/2013	8465765	Active
Orally effective methylphenidate extended	USA	Tris Pharma, Inc.	10/22/2013	8563033	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
release powder and aqueous suspension product					
Orally effective methylphenidate extended release powder and aqueous suspension product	USA	Tris Pharma, Inc.	07/15/2014	8778390	Active
Orally effective methylphenidate extended release powder and aqueous suspension product	USA	Tris Pharma, Inc.	02/17/2015	8956649	Active
Orally effective methylphenidate extended release powder and aqueous suspension product	USA	Tris Pharma, Inc.	05/26/2015	9040083	Active
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release	USA	Tris Pharma, Inc.	05/24/2022	11337920	Active
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release	USA	Tris Pharma, Inc.	04/21/2022	17725677	Pending
Clonidine formulation	USA	Tris Pharma, Inc.	01/07/2014	8623409	Active
Novel clonidine formulation	USA	Tris Pharma, Inc.	12/02/2022	18061004	Pending
Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release	USA	Tris Pharma, Inc.	05/24/2022	11337919	Active
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release	USA	Tris Pharma, Inc.	(04/21/2022)	(17725673)	Pending

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings	USA	Tris Pharma, Inc.	06/19/2012	8202542	Active
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system	USA	Tris Pharma, Inc.	12/18/2018	16955373	Active
Extended release amphetamine tablets	USA	Tris Pharma, Inc.	02/28/2023	11590081	Active
Extended release amphetamine tablets	USA	Tris Pharma, Inc.	02/02/2023	18163818	Pending
Liquid clonidine extended release composition	USA	Tris Pharma, Inc.	03/05/2024	11918689	Active
Liquid clonidine extended release composition	USA	Tris Pharma, Inc.	01/23/2024	18419883	Pending
Extended release amphetamine compositions	USA	Tris Pharma, Inc.	02/28/2023	11590228	Active
Extended release amphetamine compositions	USA	Tris Pharma, Inc.	01/19/2023	12076441	Active
Benzonatate modified release solid tablets and capsules	USA	Tris Pharma, Inc.	03/26/2024	11938224	Active
Oxybate polyethylene glycol prodrugs	USA	Tris Pharma, Inc.	(08/10/2022)	(17818733)	Pending
Process for preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds	USA	Park Therapeutics Inc	09/01/2015	9120797	Active
Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'H-	USA	Park Therapeutics Inc	03/22/2016	9289416	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine					
Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine	USA	Park Therapeutics Inc	02/09/2021	10912763	Active
Calcitonin products and therapies for treating inflammatory or degenerative diseases	USA	Park Therapeutics Inc	12/29/2015	9220758	Active
Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine	USA	Park Therapeutics Inc	07/01/2014	8765800	Active
Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine	USA	Park Therapeutics Inc	12/31/2013	8618156	Active
Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative	USA	Park Therapeutics Inc	04/26/2016	9320729	Active
Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative	USA	Park Therapeutics Inc	09/18/2018	10076510	Active
Cebranopadol for Treating Pain in Subjects with	USA	Park Therapeutics Inc	07/17/2018	10022353	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
Impaired Hepatic And/OR Impaired Renal Function					
Process for the Preparation of 5-Fluorotryptophol	USA	Park Therapeutics Inc	06/18/2019	10323040	Active
Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4'9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and a gabapentinoid	USA	Park Therapeutics Inc	04/26/2016	9320725	Active
Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4'9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and a gabapentinoid	USA	Park Therapeutics Inc	04/25/2017	9629825	Active
Method for Synthesizing Substituted Aminocyclohexanone Compounds	USA	Park Therapeutics Inc	02/25/2014	8658827	Active
Solid forms of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4'9'-dihydro-3' H-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine hydrochloride	USA	Park Therapeutics Inc	11/25/2014	8895604	Active
Crystalline (1r, 4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4'9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine	USA	Park Therapeutics Inc	12/24/2013	8614245	Active
Process for the preparation of (1r,4r)-6'-fluoro-(N,N-dimethyl- and N-methyl)-4-phenyl-4'9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine	USA	Park Therapeutics Inc	07/15/2014	8779160	Active

Patent Name	Jurisdiction	Owner	Reg. Date (App. Date)	Patent No. (App. No.)	Status
Pharmaceutical composition comprising (1R,4R)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano- [3,4,b]indol] -4-amine and paracetamol or propacetamol	USA	Park Therapeutics Inc	04/26/2022	11311504	Active
Pharmaceutical composition comprising (1r,4r) -6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and a NSAR	USA	Park Therapeutics Inc	12/16/2014	8912226	Active
Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam	USA	Park Therapeutics Inc	04/12/2016	9308196	Active
Solid forms of (1r,4r)-6'-fluoro-(N, N-dimethyl)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid	USA	Park Therapeutics Inc	12/16/2014	8912343	Active
Room temperature stable oral calcitonin formulation	USA	Park Therapeutics Inc	03/29/2022	11285113	Active
Room temperature stable oral calcitonin formulation	USA	Park Therapeutics Inc	06/04/2024	11998640	Active
Titration of Cebranopadol	USA	Park Therapeutics Inc	01/25/2022	11229625	Active